Abstract
Background The main focus of rehabilitation following hip fracture is to regain mobility.
Objectives To estimate the progression of real-world mobility the first year after hip fracture using digital mobility outcomes.
Design An exploratory, prospective cohort study with pooled data from four previously conducted clinical trials.
Setting and Subjects We combined data from the Trondheim Hip Fracture Trial and Eva-Hip Trial in Trondheim, Norway, and the PROFinD 1 and PROFinD 2 trials in Stuttgart and Heidelberg, Germany, resulting in a sample of 717 hip fracture patients aged ≥65 years.
Methods Each of the trials assessed mobility using body-fixed sensors (activPAL™) at three time points, collectively providing observations across the entire first year post-surgery. The following 24-hour DMOs were calculated: total walking duration (minutes), maximum number of steps within a walking bout, and number of sit-to-stand-to-walk transfers. Continuous one-year progression of the median, the 25th percentile, and the 75th percentile were estimated using quantile regression models with splines.
Results The dataset contained 5,909 observation days. The median daily total walking duration increased until 36 weeks post-surgery reaching 40 minutes; daily maximum number of steps within a walking bout increased during the first eight weeks and then stabilized at less than 100 steps; daily sit-to-stand-to-walk transfers reached a plateau after six weeks with less than 40 transfers.
Conclusions The three DMOs progressed differently and attained plateau levels at varying times during the first year after hip fracture, indicating that these Digital Mobility Outcomes provide complementary information about different aspects of mobility recovery.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the Norwegian University of Science and Technology, Faculty of Medicine and Health Sciences, Trondheim, Norway, and the Mobilise-D project that has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No. 820820. This JU receives support from the European Unions Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations (EFPIA). Content in this publication reflects the authors view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein. The Trondheim Hip Fracture Trial was funded by the Norwegian Research Council, the Central Norway Health Authority, the St Olav Hospital Trust, and the Department of Neuroscience at the Norwegian University of Science and Technology. The EVA-Hip Trial was funded by the Norwegian Womens Health Association and the Norwegian Extra Foundation for Health and Rehabilitation through the EXTRA funds, and the Norwegian Fund for Postgraduate Training in Physiotherapy. The PROFinD1 Trial was funded by the German Federal Ministry of Education and Research (grant number 01EC1007A). The PROFinD2 Trial was funded by the German Federal Ministry of Education and Research (grant number 01EC1404A-C).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Committee for Ethics in Medical Research in Central Norway gave ethical approval for this work (REK4.2008.335 and REK2010/3265-3). The ethical committees at the University of Stuttgart, and the Universities of Tubingen and Heidelberg gave ethical approval for this work (113/2011BO2, 150/2015BO1, and S-256/2015.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
